Gracell Biotechnologies Inc expected to post a loss of 21  cents a share - Earnings Preview

Gracell Biotechnologies

13/05/2022 16:22

* Gracell Biotechnologies Inc  GRCL.OQ   GRCL.O  is expected
to show no change in quarterly revenue when it reports 
results on May 16. 
    * ​Refinitiv's mean analyst estimate for Gracell
Biotechnologies
Inc is for a loss of 21 cents per share. For the same quarter
last year, the company reported a loss of 25 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Gracell
Biotechnologies Inc is $23​, above​ its last closing price
of $3.14. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.33       -0.33      -0.30     Beat    9.1
 Sep. 30 2021  -0.15       -0.12      -0.30     Missed  -150
 Jun. 30 2021  -0.12       -0.12      -0.20     Missed  -71.4​
 Mar. 31 2021  -0.21       -0.21      -0.25     Missed  -17.2
 ​​Dec.        -0.26       -0.26      -0.16     Beat    37.5
 31 2020                                                
                                                        ​
 This summary was machine generated May 13 at 15:22 GMT.  All
figures in US dollars  unless otherwise stated